CN108409662B - 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物 - Google Patents

作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物 Download PDF

Info

Publication number
CN108409662B
CN108409662B CN201810435608.5A CN201810435608A CN108409662B CN 108409662 B CN108409662 B CN 108409662B CN 201810435608 A CN201810435608 A CN 201810435608A CN 108409662 B CN108409662 B CN 108409662B
Authority
CN
China
Prior art keywords
compound
alkyl group
substituted
disease
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201810435608.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108409662A (zh
Inventor
约翰·P·托斯卡诺
达里尔·A·格思里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN108409662A publication Critical patent/CN108409662A/zh
Application granted granted Critical
Publication of CN108409662B publication Critical patent/CN108409662B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201810435608.5A 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物 Expired - Fee Related CN108409662B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
US61/548,036 2011-10-17
CN201280051009.4A CN104053647B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280051009.4A Division CN104053647B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Publications (2)

Publication Number Publication Date
CN108409662A CN108409662A (zh) 2018-08-17
CN108409662B true CN108409662B (zh) 2021-10-26

Family

ID=47143299

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810435608.5A Expired - Fee Related CN108409662B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
CN201280051009.4A Expired - Fee Related CN104053647B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280051009.4A Expired - Fee Related CN104053647B (zh) 2011-10-17 2012-10-16 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物

Country Status (13)

Country Link
US (3) US9181213B2 (enExample)
EP (1) EP2776402B1 (enExample)
JP (1) JP6177246B2 (enExample)
KR (1) KR102061537B1 (enExample)
CN (2) CN108409662B (enExample)
AU (2) AU2013201929B2 (enExample)
BR (1) BR112014009282B1 (enExample)
CA (1) CA2852914C (enExample)
HK (1) HK1200168A1 (enExample)
IL (1) IL232101A (enExample)
MX (1) MX363306B (enExample)
SG (1) SG11201401587QA (enExample)
WO (1) WO2013059194A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409662B (zh) 2011-10-17 2021-10-26 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
MX363843B (es) 2013-01-18 2019-04-05 Cardioxyl Pharmaceuticals Inc Composiciones farmaceuticas que comprenden donadores de nitroxilo.
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
EP3148972B1 (en) * 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3313831B1 (en) * 2015-06-26 2021-03-10 The Johns Hopkins University N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US10730828B2 (en) 2015-10-19 2020-08-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
KR20190070912A (ko) * 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산
CN110520116A (zh) 2017-01-03 2019-11-29 卡尔迪奥克斯尔制药公司 供硝酰化合物的给予方法
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
CN101472576A (zh) * 2006-03-17 2009-07-01 约翰斯·霍普金斯大学医学院 作为新的有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
WO2011071947A2 (en) * 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
CA2306914A1 (en) 1997-10-24 1999-05-06 Shionogi & Co., Ltd. Antirheumatic
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2007522135A (ja) 2004-01-30 2007-08-09 ザ ジョンズ ホプキンス ユニバーシティ ニトロキシル前駆化合物および使用方法
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CA2613477C (en) 2005-06-23 2013-12-03 Johns Hopkins University Thiol-sensitive positive inotropes
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
US8227639B2 (en) 2007-09-26 2012-07-24 Cardioxyl Pharmaceuticals N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
DK2278975T3 (en) 2008-05-07 2016-12-19 Cardioxyl Pharmaceuticals Inc NOVEL nitroso compounds WHICH NITROXYLDONORER AND METHODS OF USE THEREOF
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CA2782110A1 (en) 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
CN108409662B (zh) 2011-10-17 2021-10-26 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
MX363843B (es) 2013-01-18 2019-04-05 Cardioxyl Pharmaceuticals Inc Composiciones farmaceuticas que comprenden donadores de nitroxilo.
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
CN101472576A (zh) * 2006-03-17 2009-07-01 约翰斯·霍普金斯大学医学院 作为新的有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
WO2011071947A2 (en) * 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development of N-Substituted Hydroxylamines as Efficient Nitroxyl (HNO) Donors;Daryl A. Guthrie，等;《J. Am. Chem.Soc.》;20120109;第134卷;1962-1965 *
Production of nitroxyl (HNO) at biologically relevant temperatures from the retro-Diels-Alder reaction of N-hydroxyurea-derived acyl nitroso-9,10-dimethylanthracene cycloadducts;Yueping Xu，等;《Tetrahedron Letters》;20001231;第41卷;4265-4269 *

Also Published As

Publication number Publication date
KR102061537B1 (ko) 2020-01-03
IL232101A (en) 2017-04-30
CA2852914A1 (en) 2013-04-25
US9862699B2 (en) 2018-01-09
JP2015501308A (ja) 2015-01-15
HK1200168A1 (en) 2015-07-31
SG11201401587QA (en) 2014-07-30
EP2776402A1 (en) 2014-09-17
US20170050947A1 (en) 2017-02-23
CN104053647A (zh) 2014-09-17
CA2852914C (en) 2019-11-26
BR112014009282B1 (pt) 2021-12-14
IL232101A0 (en) 2014-05-28
WO2013059194A1 (en) 2013-04-25
US9499511B2 (en) 2016-11-22
AU2013201929A1 (en) 2013-05-02
BR112014009282A2 (pt) 2017-06-13
US20140275134A1 (en) 2014-09-18
MX2014004596A (es) 2014-09-04
BR112014009282A8 (pt) 2020-04-22
JP6177246B2 (ja) 2017-08-09
US9181213B2 (en) 2015-11-10
KR20140107197A (ko) 2014-09-04
US20160115148A1 (en) 2016-04-28
AU2015246114A1 (en) 2015-11-12
MX363306B (es) 2019-03-20
EP2776402B1 (en) 2017-07-26
AU2013201929B2 (en) 2015-07-23
CN104053647B (zh) 2018-06-01
CN108409662A (zh) 2018-08-17

Similar Documents

Publication Publication Date Title
CN104053647B (zh) 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
US9458127B2 (en) Bis-acylated hydroxylamine derivatives
JP5826762B2 (ja) Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体
WO2022129047A2 (en) Novel modulators of the nmda receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211026

CF01 Termination of patent right due to non-payment of annual fee